Cubist Systematic Strategies LLC Makes New $5.92 Million Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Cubist Systematic Strategies LLC bought a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the 4th quarter, Holdings Channel reports. The institutional investor bought 446,764 shares of the company’s stock, valued at approximately $5,915,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in Takeda Pharmaceutical by 15,449.0% during the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company’s stock valued at $6,629,000 after purchasing an additional 497,457 shares in the last quarter. Summit Global Investments increased its stake in shares of Takeda Pharmaceutical by 75.5% in the 4th quarter. Summit Global Investments now owns 729,200 shares of the company’s stock valued at $9,655,000 after purchasing an additional 313,642 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Takeda Pharmaceutical by 14.6% during the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company’s stock worth $24,806,000 after buying an additional 238,161 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth $2,558,000. Finally, Crossmark Global Holdings Inc. boosted its stake in Takeda Pharmaceutical by 284.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after buying an additional 155,795 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $14.29 on Friday. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The company has a market cap of $45.45 billion, a price-to-earnings ratio of 35.71, a PEG ratio of 0.24 and a beta of 0.26. The firm has a 50 day simple moving average of $14.88 and a 200 day simple moving average of $13.99.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.